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Pathways in the B7:CD28 family of costimula-
tory molecules regulate T cell activation and
tolerance. B7-dependent responses in Cd28/
Ctla4/ T cells together with reports of stimula-
tory and inhibitory functions for Programmed
Death-1 Ligand 1 or 2 molecules (PD-L1 or
PD-L2) have suggested additional receptors for
these B7 family members. We show that B7-1
and PD-L1 interacted with affinity intermediate
to that of B7-1:CD28 and B7-1:CTLA-4. The
PD-L1:B7-1 interface overlapped with the B7-
1:CTLA-4 and PD-L1:PD-1 (Programmed
Death-1) interfaces. T cell activation and cyto-
kine production were inhibited by the interac-
tion of B7-1 with PD-L1. The responses of PD-
1-deficient versus PD-1,B7-1 double-deficient
T cells to PD-L1 and of CD28,CTLA-4 double-
deficient versus CD28,CTLA-4,PD-L1 triple-
deficient T cells to B7-1 demonstrated that
PD-L1 and B7-1 interact specifically to inhibit
T cell activation. Our findingspoint to a substan-
tial bidirectional inhibitory interaction between
B7-1 and PD-L1 and add an additional dimen-
sion to immunoregulatory functions of the
B7:CD28 family.
INTRODUCTION
Pathways in the B7:CD28 family of costimulatory mole-
cules provide critical signals that regulate T cell activation
and tolerance (Chen, 2004; Chikuma andBluestone, 2003;
Greenwald et al., 2005). The pathway consisting of B7-1
(CD80) and B7-2 (CD86) costimulatory molecules with the
CD28 and CTLA-4 (CD152) receptors is the best charac-
terized pathway but is complex because of the dual spec-
ificity of B7-1 and B7-2 for CD28 and CTLA-4. CD28 is
constitutively expressed on T cells and its activation en-
hances T cell receptor (TCR) signaling. The higher affinityreceptor CTLA-4 is rapidly induced in T cells upon TCR
stimulation and its engagement diminishes TCR signaling.
The B7-1 and B7-2 molecules differ in their expression
on antigen-presenting cells (APCs): B7-2 is constitutively
expressed in low amounts and rapidly upregulated,
whereas B7-1 is inducibly expressed later than B7-2.
B7-1 and B7-2 not only are expressed on APCs, but also
are expressed on T cells. Although the function of B7-1
and B7-2 as costimulatory molecules on APCs is well
established, their roles on T cells are less well understood.
Recent studies have suggested that B7 on T cells may
serve to downregulate responses and deliver signals into
T cells. B7-1 deficiency on T cells resulted in accelerated
graft-versus-host disease in a model of allogeneic bone-
marrow transplantation (Taylor et al., 2004), and B7-1 ex-
pression on effector T cells was shown to be required for
suppression by regulatory T cells in a colitis model (Paust
et al., 2004).
Over the past several years, the B7:CD28 family of cos-
timulatory molecules has grown. One of the newer path-
ways comprises the Programmed Death-1 (PD-1) recep-
tor (CD279) and its two ligands, PD-L1 (B7-H1; CD274)
(Dong et al., 1999; Freeman et al., 2000) and PD-L2
(B7-DC; CD273) (Latchman et al., 2001; Tseng et al.,
2001). In contrast to CD28 and CTLA-4, PD-1 is inducibly
expressed on T cells, B cells, andmonocytes upon activa-
tion (Okazaki et al., 2002). The two PD-1 ligands differ
in their expression patterns: PD-L1 is constitutively ex-
pressed and upregulated to higher amounts on murine
hematopoietic cells (e.g., T cells, B cells, macrophages,
dendritic cells [DCs], and bone-marrow-derived mast
cells) and nonhematopoietic cells (e.g., endothelial, epi-
thelial, and muscle cells), whereas PD-L2 is only inducibly
expressed on DCs, macrophages, and bone-marrow-
derived mast cells.
The roles that PD-L1 and PD-L2 play in T cell activation
are only beginning to be understood. Although a number
of studies have demonstrated inhibitory functions for
PD-L1 and PD-L2, others reported that PD-L1 and PD-L2
can stimulate T cell proliferation and cytokine production
(Dong et al., 1999, 2002). The reasons for the contradic-
tory results of these functional studies are not yet clear.
Although a second stimulatory receptor for PD-Ls hasImmunity 27, 111–122, July 2007 ª2007 Elsevier Inc. 111
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PD-L1 Interacts with B7-1 to Inhibit T Cellsbeen postulated (Dong and Chen, 2006; Liu et al., 2003;
Shin et al., 2003), it has yet to be identified.
Our studies of T cells lacking CD28 and CTLA-4 provide
evidence for an additional functional receptor for B7-1 or
B7-2 on T cells. When stimulated with anti-CD3 in the
presence of wild-type APCs, wild-type T cells proliferate
more than CD28,CTLA-4 double-deficient T cells. How-
ever, the proliferation of both wild-type and CD28,CTLA-4
double-deficient T cells is reduced when CTLA-4-Ig was
added to the cultures (Mandelbrot et al., 2001). These
results motivated us to search for an additional receptor
for B7-1 or B7-2.
Here we identify B7-1 and PD-L1 as binding partners.
Expression cloning via a cDNA library prepared from
Cd28/Ctla4/ T cells revealed PD-L1 as a binding part-
ner for B7-1. We used biophysical techniques to demon-
strate that B7-1 could specifically bind to PD-L1 and char-
acterized the affinity of their interaction as being
intermediate to that of B7-1 with CD28 and B7-1 with
CTLA-4. By using protein crosslinking and mass spec-
trometry, we showed that the interaction site between
these two proteins overlapped the B7-1:CTLA-4 interface
and the PD-L1:PD-1 interface. Finally, functional studies
indicated that the B7-1:PD-L1 interaction can inhibit
T cell proliferation and cytokine production. These
findings reveal an additional means by which B7-1 and
PD-L1 can regulate T cell responses and lead to a revised
view of the functions of pathways within the B7:CD28
family of costimulatory molecules.
RESULTS
Identification of PD-L1 as a Ligand for B7-1
We sought other binding partners for B7-1 from a cDNA
library made from mRNA of activated Cd28/Ctla4/
CD4 T cells (Mandelbrot et al., 1999). The cDNA library
was transfected into COS cells and panned on a plate
coated with B7-1-Ig fusion protein. After three rounds of
immunoselection, cDNA plasmids from adherent cells
were sequenced. All of the plasmids (of six sequenced)
revealed a cDNA encoding mPD-L1 (Figure S1 in the Sup-
plemental Data available online). The cDNA clones varied
slightly in the length of the 50 untranslated region, indicat-
ing that the Cd274 gene encoding PD-L1 was indepen-
dently isolated multiple times. These findings suggested
that PD-L1 transfected into COS cells bound immobilized
B7-1.
Surface Plasmon Resonance Establishes
B7-1:PD-L1 Affinity
To investigate whether B7-1 can associate with PD-L1, we
employed the technique of surface plasmon resonance
and followed the interaction of PD-L1, B7-1, or control
proteins. We immobilized PD-L1-Ig and PD-L2-Ig and
injected B7-1-Ig and B7-2-Ig at various concentrations,
and vice versa. We calculated affinities from equilibrium
binding to eliminate considerations of mass transport and
to avoid the complexities of kinetic analyses of divalent
ligands (kinetic data for B7-1 binding to and dissociating112 Immunity 27, 111–122, July 2007 ª2007 Elsevier Inc.from immobilized PD-L1 are shown in Figure S2A). There
was a specific interaction between B7-1 and PD-L1 with
a dissociation constant (KD) of 1.9 mM. In the reversed
experiment where B7-1 was immobilized and PD-L1 in-
jected, a KD of 1.5 mMwas determined (Figure 1). By com-
parison, the binding affinities of PD-1 to PD-L1 or PD-L2
Figure 1. Equilibrium Binding Constants of B7-1 and PD-L1
Interactions
(A) Equilibrium binding responses were measured by surface plasmon
resonance of fusion proteins of B7-1, B7-2, and PD-1 to immobilized
PD-L1 and PD-L2 fusion proteins. No binding response was seen for
B7-2 to PD-L1 or PD-L2 (not shown). The KDs for the three important
interactions are shown (arrows).
(B) Scatchard plot shows the dissociation constant for B7-1 to immo-
bilized PD-L1 is 1.6 mM. The linear fit and its 90% confidence interval
are shown.
(C) Summary of dissociation constants obtained from Biacore equilib-
rium binding experiments.
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PD-L1 Interacts with B7-1 to Inhibit T CellsFigure 2. Localization of the B7-1:PD-L1
Binding Site
Molecular model of (A) B7-1 and (B) PD-L1
showing sites of interaction identified by cross-
linking. On each structure, lysines are colored:
site 1 lysines are colored red, site 2 lysine(s) are
colored orange, and site 3 lysine(s) are colored
green. The binding site for CTLA-4 (Stamper
et al., 2001) is shown in yellow on the B7-1
model, and the binding site for PD-1 (Wang
et al., 2003) is shown in yellow on the PD-L1
model. Dotted lines are shown to summarize
the putative B7-1:PD-L1 binding site. There
is partial overlap among the B7-1:CTLA-4,
B7-1:PD-L1, and PD-L1:PD-1 interfaces.were approximately three times stronger (KD of 0.59 and
0.77 mM, respectively), and CTLA-4 for B7-1 was about
seven times stronger (KD of 0.31 mM; equilibrium binding
data for B7-1:CTLA-4 shown in Figure S2B). Our dissoci-
ation constants were similar to those published for PD-L1
and PD-L2 to PD-1 (0.52 mM and 0.26 mM, respectively)
(Youngnak et al., 2003) and for B7-1 and B7-2 to CTLA-
4(0.2 mM and 2.6 mM, respectively) (Collins et al., 2002;
van der Merwe et al., 1997). We did not observe any spe-
cific interaction between B7-1 and PD-L2, between B7-2
and PD-L1 or PD-L2, nor with control proteins. These
results show a specific and unique interaction between
PD-L1 and B7-1, with an affinity (1.7 mM) intermediate
between the affinities of B7-1 for CD28 (4 mM) and
CTLA-4 (0.2 mM) and of PD-L1 for PD-1 (0.5 mM).
To independently measure the dissociation constant
between B7-1 and PD-L1 in solution, we performed ana-
lytical ultracentrifugation of the proteins individually and
together at a concentration above their putative KD.
When B7-1 and PD-L1 were mixed, they shifted their con-
centration gradient at equilibrium, yielding a dissociation
constant of 1.6 mM (Figure S3). Additionally, dynamic light
scattering with the B7-1, PD-L1, PD-L2, and CTLA-4
fusion proteins revealed a statistically significant increase
in complex size for B7-1:PD-L1 (p = 0.01) and B7-1:CTLA-4
(p < 0.001). No increase in size was observed when
PD-L1-Ig was incubated with a control Ig fusion protein
(Figure S4). These results confirm that a specific, high-
affinity interaction exists between B7-1 and PD-L1.
Chemical Crosslinking Reveals Binding
Site for PD-L1 on B7-1
To determine which molecular surfaces of the B7-1 and
PD-L1 molecules are involved in their binding, we per-
formed crosslinkingwith the heterobifunctional crosslinker
sulfo-SBED. B7-1-Igwas linked to sulfo-SBED,mixedwith
PD-L1-Ig, and crosslinked with UV light. The complex was
separated by nonreducing SDS-PAGE and stained withCoomassie blue (Figure S5A). The band corresponding
to a molecular weight equal to the sum of the B7-1-Ig
and PD-L1-Ig was excised, washed, and subjected to pro-
teolysis with chymotrypsin. The resulting fragments were
analyzed by mass spectrometry, and a database search
revealed that peptides from both B7-1 and PD-L1 were
among these fragments. To determine whether the frag-
ments were physically linked, we subjected them to high-
resolution quadrupole-TOF mass spectrometry and com-
piled a list of fragments containing a peptide from B7-1, a
peptide from PD-L1, plus the crosslinker. This list showed
three principal areas of crosslinking between B7-1 and
PD-L1 (Figure S5B) that comprised 84% of the annotated
peptides (Figure S5C).
Because sulfo-SBED has flexible arms, the lysine resi-
dues from these crosslinked peptides provide a boundary
to the interface of interaction for B7-1 and PD-L1. To iden-
tify the B7-1:PD-L1 interaction site, we mapped these
lysines onto the crystal structure of B7-1 andonto amolec-
ular model of PD-L1 that we generated from the structure
of B7-1 (Ikemizu et al., 2000). We also superimposed the
putative binding sites for CTLA-4 (Stamper et al., 2001)
and PD-1 (Wang et al., 2003) onto the models (Figures
2A and 2B). These mappings show that the B7-1 and
PD-L1 interaction occurs on the GFCC0C00 face of B7-1,
suggesting a partial overlap with that of B7-1:CTLA-4.
Likewise, the PD-L1 side of theB7-1:PD-L1 interface over-
lapsat least partiallywith theputativeGFCC0C00 faceof PD-
L1:PD-1 in that they share two lysines (K124 and K129).
The partial overlap of the B7-1:PD-L1 interface with those
of B7-1:CTLA-4 and PD-L1:PD-1 suggests that CTLA-4,
CD28, and PD-L1 could compete for binding to B7-1. Sim-
ilarly, B7-1 and PD-1 may compete for binding to PD-L1.
Cell-Adhesion Assay Shows that Cell-Surface
B7-1:PD-L1 Can Interact
To verify the interaction between B7-1 and PD-L1 when
these proteins are expressed on living cells and to furtherImmunity 27, 111–122, July 2007 ª2007 Elsevier Inc. 113
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PD-L1 Interacts with B7-1 to Inhibit T CellsFigure 3. Cell-Adhesion Assay Shows Specific Binding of B7-1 to PD-L1
(A) Adhesion assay with 300.19-B7-1 cells shows specific binding to PD-L1. The mouse pre-B cell line 300.19 was stably transfected with mB7-1
(300.19-B7-1) and labeled with BCECF. Some cells were preincubated with 40 mg/mL of B7-1 mAb or CTLA-4-Ig, as indicated. Wells were coated
with PD-L1-Ig, PD-L2-Ig, CTLA-4-Ig, or hIgG1-Fc and blocked. Fluorescent 300.19-B7-1 cells were introduced into the wells. Fluorescencewasmea-
sured before and after washing. Untransfected 300.19 cells showed less than 1% binding to similarly coated wells (not shown).
(B) Adhesion assay with 300.19 cells stably transfected withmPD-L1 (300.19-PD-L1) demonstrates the differential ability of two PD-L1mAbs to block
the interaction between PD-L1 and PD-1.
(C) Adhesion assay with 300.19-PD-L1 cells shows specific binding to B7-1. Wells were coated with B7-1-Ig, B7-2-Ig, PD-1-Ig, or hIgG1-Fc and
blocked, and then some cells were incubated with 20 mg/mL of the indicated mAbs. 300.19-PD-L1 cells were labeled with BCECF and introduced
into the wells, and fluorescence was measured before and after washing. Untransfected 300.19 cells showed less than 4% binding (not shown).
Averaged percent cells bound with error bars of one standard deviation are shown.characterize the B7-1:PD-L1 interaction, we used an avid-
ity-based cell-adhesion assay. We found that mB7-1
transfectants of 300.19 cells adhered toCTLA-4-Ig-coated
wells (80%of cells bound) and PD-L1-Ig (40%binding)
but not to PD-L2-Ig- or hIgG1-Fc-coated wells (<5%)
(Figure 3A). Untransfected 300.19 cells did not adhere to
any of the wells (<1%, not shown). To demonstrate that
the binding to PD-L1 was specifically due to B7-1, we pre-
incubated the cellswith B7-1mAbs (clones 16-10A1 [Razi-
Wolf et al., 1992] or 1G10 [Nabavi et al., 1992]), CTLA-4-Ig,
or a control IgG1. Both B7-1 mAbs could bind to B7-1 on
the transfected 300.19 cells but did not bind to control
300.19 cells (data not shown). The 1G10 antibody and
CTLA-4-Ig blocked the interaction between B7-1 on the
300.19-B7-1 cells and PD-L1 on the plate (p < 0.01), con-
firming that the adhesion of the cells to the plate-bound
PD-L1 was due to B7-1. The other B7-1 antibody (16-
10A1) and the rat control antibody did not block adhesion
to PD-L1 (Figure 3A). These results suggest that 1G10 and
16-10A1 engage different epitopes on B7-1 and that only
the 1G10 epitope overlaps with that of the B7-1:PD-L1
interface. The partial blocking by CTLA-4-Ig confirms an
overlap of the B7-1:PD-L1 binding interface with that of
the CTLA-4 binding site on B7-1.
To independently characterize the B7-1:PD-L1 interac-
tion, we repeated the adhesion assay with 300.19 cells
transfected with mPD-L1 and allowed them to engage
plate-bound B7-1-Ig. We used the following mAbs to
characterize the specificity of the interaction: two PD-L1114 Immunity 27, 111–122, July 2007 ª2007 Elsevier Inc.antibodies (Figure 3B), one of which blocks the PD-L1:
PD-1 interaction (10F.9G2 [Rodig et al., 2003]) andone that
does not (10F.2H11), as well as the two B7-1 antibodies
used above. 300.19-PD-L1 cells bound PD-1 (68% bind-
ing) and B7-1 (36% binding), but not B7-2 (1% binding)
(Figure 3C). Both PD-L1 antibodies and the 1G10 B7-1
antibody were able to block the PD-L1:B7-1 interaction.
CTLA-4-Ig, PD-L1-Ig, and PD-1-Ig showed intermediate
ability to block the PD-L1:B7-1 interaction, which corrob-
orates their overlapping interfaces. These results together
confirm that B7-1 and PD-L1 expressed on cell surfaces
can interact and that this interaction can be specifically
blocked.
In Vitro Proliferation of CD28,CTLA-4 Double-
Deficient T Cells Is Inhibited by B7-1-Coated Beads
To investigate the functional significanceofB7-1:PD-L1 in-
teractions, we utilized T cells from mice lacking the well-
characterized receptors for B7-1 or PD-L1. We compared
responses of Cd28/Ctla4/, Pdcd1/, or wild-type
C57BL/6 (WT) CD4 T cells to beads covalently coupled
with stimulatory CD3 antibody (clone 2C11) along with
B7-1-Ig or PD-L1-Ig (termed B7-1+CD3 or PD-L1+CD3)
or coupled with an Ig fusion control (termed Ig+CD3).
We first examined the effect of B7-1+CD3 beads on
responses of Cd28/Ctla4/ versus WT CD4 T cells.
WT T cells demonstrated the expected increase in prolif-
eration when cultured with B7-1+CD3 beads compared
to Ig+CD3 beads. In contrast, Cd28/Ctla4/ T cells
Immunity
PD-L1 Interacts with B7-1 to Inhibit T CellsFigure 4. Proliferation of Cd28/Ctla4/ T Cells Is Reduced by B7-1
Cd28/Ctla4/ or WT CD4 T cells were stimulated with beads coated with anti-CD3 plus either B7-1-Ig (‘‘B7-1’’) or hIgG1Fc (‘‘Ig’’) control.
(A) T cell proliferation was measured by 3H-thymidine incorporation for the last 16 hr of a 64 hr culture. These results are representative of at least
5 independent experiments. Averaged 3H-thymidine incorporation with error bars of one standard deviation are shown.
(B) T cell expansion was measured by flow cytometric analysis of CFSE dilution at 64 hr. These results are representative of 3 independent exper-
iments.
(C) Cytokines were measured by BD Cytokine Bead Array in supernatants obtained at 48 hr. Averaged cytokine concentration with error bars of one
standard deviation are shown.proliferated less when cultured with B7-1+CD3 beads as
compared to Ig+CD3 beads (p < 0.0001) (Figure 4A). To
further elucidate T cell responses, we measured T cell ex-
pansion by 5-(and-6)-carboxyfluorescein diacetate, suc-
cinimidyl ester (CFSE) dilution. Analysis of CFSE dilution
at 64 hr of culture with the same beads as above recapit-
ulated the results of thymidine incorporation. Compared
to Ig+CD3 beads, B7-1+CD3 beads increased expansion
of WT T cells but inhibited Cd28/Ctla4/ T cells
(Figure 4B). B7-2+CD3 beads could costimulate WT T
cells but did not inhibit proliferation of Cd28/Ctla4/
T cells, providing further evidence of the specificity of
the B7-1:PD-L1 interaction (data not shown). Cd28/
Ctla4/ T cells produced markedly less (60%) IFN-g,
TNF-a, and IL-2 when cultured with B7-1+CD3 beads as
compared to Ig+CD3 beads (p = 0.05) (Figure 4C). IL-4
and IL-5 were low but also reduced in cultures of Cd28/
Ctla4/ T cells with B7-1+CD3 beads compared to WT
T cells (not shown).
To further examine the effect of B7-1 signaling on T cell
activation, we evaluated cell-surfacemarkers of activation
and the expression of costimulatory molecules on T cells
by flow cytometry. When Cd28/Ctla4/ T cells were
cultured with B7-1+CD3 beads, they showed decreased
expression of CD69, CD25, and CD44 as early as day 1
and also on day 2 (Figure 5A) as compared to Ig+CD3
beads. B7-2, PD-L1, and ICOS were also upregulated
less on Cd28/Ctla4/ T cells cultured with B7-1+CD3beads (Figure 5B), whereas B7-1, PD-1, CTLA-4 (Fig-
ure 5B), and IL7R-a (not shown) showed scant differences
between groups. These studies demonstrate that an in-
hibitory signal can be delivered by B7-1 to Cd28/
Ctla4/ T cells resulting in decreased proliferation, cyto-
kine production, and expression of activation markers.
In Vitro Proliferation of PD-1-Deficient T Cells
Is Inhibited by PD-L1-Coated Beads
To determine whether the B7-1:PD-L1 interaction could
operate bidirectionally, and thus whether PD-L1 could de-
liver a signal via B7-1 on the T cell surface, we reversed the
experimental setup. To eliminate the known receptor of
PD-L1, we used Pdcd1/ T cells and examined the effect
of PD-L1+CD3 beads as compared to Ig+CD3 beads.
Pdcd1/ T cells proliferated less and produced less IL-2
and IFN-g after incubation with PD-L1+CD3 beads com-
pared to Ig+CD3 beads (p < 0.0001) (Figures 6A and
6C). IL-4 or IL-5 production was low but similarly reduced
by PD-L1+CD3 beads, but not to as great an extent as
with Cd28/Ctla4/ T cells stimulated by B7-1+CD3.
Compared to Ig+CD3 beads, PD-L1+CD3 beads inhibited
the expansion of PD-1-deficient T cells as well as WT T
cells (Figure 6B). In contrast, PD-L2+CD3 beads did not
inhibit Pdcd1/ T cells but did inhibit expansion of WT
T cells (data not shown). These results indicate that there
is an inhibitory counter-receptor for PD-L1 but not PD-L2Immunity 27, 111–122, July 2007 ª2007 Elsevier Inc. 115
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PD-L1 Interacts with B7-1 to Inhibit T CellsFigure 5. Markers of Activation Are Diminished in Cd28/Ctla4/ T Cells Stimulated with Anti-CD3 Plus B7-1
Cd28/Ctla4/ CD4 T cells were cultured with beads coated with anti-CD3 plus either B7-1-Ig (‘‘B7-1’’) or hIgG1Fc (‘‘Ig’’). T cells were then stained
and analyzed by FACS after 24 or 48 hr for (A) activation markers and (B) costimulatory receptors and ligands. Shaded histogram indicates control
cells.on Pdcd1/ T cells, consistent with the capacity of B7-1
to bind to PD-L1 but not PD-L2.
In Vitro Confirmation of B7-1:PD-L1 Specificity
To further evaluate the specificity of the interaction be-
tween PD-L1 and B7-1, we generated PD-1,B7-1 dou-
ble-deficient mice and CD28,CTLA-4,PD-L1 triple-defi-
cient mouse strains, i.e., mice deleted of all receptors for
PD-L1 or B7-1. To test whether B7-1 acts specifically
through PD-L1 to inhibit T cell proliferation, we compared
the responses of Cd28/Ctla4/ and Cd28/Ctla4/
Cd274/ T cells to B7-1-Ig and anti-CD3. B7-1-Ig in-
hibited the expansion of Cd28/Ctla4/ T cells in re-
sponse to anti-CD3 (p = 0.05). However, B7-1-Ig failed
to inhibit the expansion of Cd28/Ctla4/Cd274/ T
cells in response to anti-CD3 (p = 0.38) (Figure 7A). These
results show that B7-1 acts specifically through PD-L1 to
inhibit T cell proliferation in the absence of CD28 and
CTLA-4. When PD-L1 is further eliminated from Cd28/
Ctla4/ cells, B7-1-Ig cannot exert its inhibitory effects.116 Immunity 27, 111–122, July 2007 ª2007 Elsevier Inc.In complementary studies, we evaluated whether
PD-L1 acts specifically through B7-1 on T cells to inhibit
T cell proliferation by comparing the responses of PD-1-
deficient and PD-1,B7-1 double-deficient T cells to PD-
L1-Ig and anti-CD3. PD-L1-Ig decreased the proliferation
of WT (p = 0.01) and PD-1-deficient (p = 0.02) T cells in
response to anti-CD3 to a statistically significant extent,
as seen in six replicate experiments. PD-L1-Ig slightly re-
duced proliferation of PD-1,B7-1 double-deficient T cells,
but this was not statistically significant (p = 0.29)
(Figure 7B). Thus, these studies show that PD-L1 can
exert an inhibitory effect on T cells either through B7-1
or PD-1. Taken together, the results demonstrate a
specific and significant bidirectional interaction between
B7-1 and PD-L1 that inhibits T cell responses.
DISCUSSION
In this report, we identify a previously unsuspected, spe-
cific interaction between two B7 family members, B7-1
Immunity
PD-L1 Interacts with B7-1 to Inhibit T CellsFigure 6. Proliferation of Pdcd1/ T Cells Is Reduced by PD-L1
Pdcd1/ or WT T cells were stimulated with beads coated with anti-CD3 plus either PD-L1-Ig (‘‘PD-L1’’) or hIgG1Fc (‘‘Ig’’) control.
(A) T cell proliferation was measured by 3H-thymidine incorporation for the last 16 hr of a 64 hr culture. These results are representative of at least 3
independent experiments. Averaged 3H-thymidine incorporation with error bars of one standard deviation are shown.
(B) T cell expansion was measured by flow cytometric analysis of CFSE dilution at 64 hr. These results are representative of 3 independent exper-
iments.
(C) Cytokines were measured by BD Cytokine Bead Array in supernatants obtained at 48 hr. Averaged cytokine concentration with error bars of one
standard deviation are shown.and PD-L1, and demonstrate that this interaction is func-
tionally significant. Signals through B7-1 or PD-L1 are in-
hibitory, resulting in diminished expression of cell-surface
activation markers, decreased T cell proliferation, and
reduced cytokine production. The direct interaction be-
tween these two molecules adds a new dimension to the
immunoregulatory interactions within the B7:CD28 family
of costimulatory molecules and compels a revised view
of the interactions among molecules within the B7:CD28
family in regulating T cell activation and tolerance. Our
work also gives increased significance to B7-1 and
PD-L1 on T cells.
The B7-1:PD-L1 interaction has a dissociation constant
of 1.7 mM, which is relatively strong compared to that of
B7-1:CD28 (4 mM) (van der Merwe et al., 1997). This find-
ing implies that B7-1 on an APC might preferentially ligate
PD-L1 on a resting T cell rather than CD28, which would
result in some degree of inhibition. Indeed, Cd274/ T
cells were shown to have augmented cytokine production
compared to wild-type T cells in vitro and to regulate path-
ogenic effector T cells in vivo (Latchman et al., 2004).
These findings take on greater significance in light of the
B7-1:PD-L1 interaction.
Both PD-L1 and B7-1 are induced on T cells upon acti-
vation, but detailed kinetics of their relative expression on
T cells during an immune response and the stimuli that
regulate their expression on T cells are not clear. In our
in vitro studies comparing responses of T cells lackingthe well-described receptors for B7-1 (Cd28/Ctla4/)
with T cells also lacking the newly identified receptor for
B7-1 (Cd28/Ctla4/Cd274/), loss of PD-L1 removed
a strong inhibitory signal (Figure 7A). When the responses
of T cells lacking the previously known receptor for PD-L1
(Pdcd1/) were compared with T cells also lacking the
new receptor for PD-L1 (Pdcd1/Cd80/), there was
also a reduction in inhibitory signals (Figure 7B), but the ef-
fects were less robust than those observed when PD-L1
was eliminated from T cells. We repeatedly observed
higher levels of expression of PD-L1 relative to B7-1 on
T cells in our in vitro cultures (Figure 5). The inhibitory ef-
fects seen in this reductionist systemmay reflect these ex-
pression differences. An inhibitory role of B7-1 on T cells is
also supported by the findings that B7-1-deficient CD4 T
cells proliferated more than WT T cells when stimulated
with specific antigen (Schweitzer and Sharpe, 1999) or
anti-CD3 in vitro and accelerated graft-versus-host dis-
ease in a mouse model of bone-marrow transplantation
(Taylor et al., 2004). In addition, studies have pointed to
an inhibitory role for B7-1 on effector T cells in suppression
by regulatory T cells in a colitis model (Paust et al., 2004).
Our results suggest that these inhibitory effects of B7-1 on
T cells may be due to interaction with PD-L1 on DCs, or
PD-L1 or CTLA-4 on regulatory T cells.
The molecular interface of the B7-1:PD-L1 interaction
and those of B7-1:CTLA-4 or PD-L1:PD-1 overlap, provid-
ing a biophysical explanation for distinct functionalImmunity 27, 111–122, July 2007 ª2007 Elsevier Inc. 117
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actions
The responses of PD-1-deficient (Pdcd1/)
versus PD-1,B7-1 double-deficient (Pdcd1/
CD80/) T cells to PD-L1 and of
CD28,CTLA-4 double-deficient (Cd28/
Ctla4/) versus CD28,CTLA-4,PD-L1 triple-
deficient (Cd28/Ctla4/Cd274/) T cells
to B7-1were used to demonstrate the specific-
ity of B7-1:PD-L1 interactions.
(A) WT, Cd28/Ctla4/, or Cd28/Ctla4/
Cd274/ CD4 T cells were cultured in wells
coated with anti-CD3 antibody (10 mg/mL)
plus either B7-1-Ig (10 mg/mL) or control Ig
(10 mg/mL). CFSE dilution was examined by
flow cytometry at 48 hr.
(B) WT, Pdcd1/, or Pdcd1/CD80/CD4 T
cells were cultured in wells coated with anti-
CD3 antibody (5 mg/mL) plus either PD-L1-Ig
(10 mg/mL) or control Ig (10 mg/mL). CFSE dilu-
tion was examined by flow cytometry at 48 hr.outcomes of blockade of PD-L1, PD-L2, and PD-1 by
mAbs in mouse models of colitis (Kanai et al., 2003), con-
tact hypersensitivity (Tsushima et al., 2003), asthma (Mat-
sumoto et al., 2004), and allogeneic heart transplantation
(Ito et al., 2005). In general, these studies found a greater
effect of anti-PD-L1 blockade as comparedwith anti-PD-1
or anti-PD-L2 blockade, which has been attributed to
differences in the expression of PD-L1 and PD-L2 or to
the half-life or affinities of the antibodies. We have found
dual-specific PD-L1 antibodies that can block two inhibi-
tory interactions, PD-L1:PD-1 and PD-L1:B7-1. In con-
trast, blockade of PD-1 or PD-L2 would affect only one
pathway. PD-L1 antibodies that block solely PD-L1:PD-1
or PD-L1:B7-1 interactions should have reduced effects
on T cell activation as compared to the dual-specific
PD-L1 mAb.
The PD-L1:B7-1 interaction may be relevant to recent
studies showing that ‘‘exhausted’’ T cells in chronic viral
infections can be rejuvenated by PD-L1 antibody (Day
et al., 2006; Freeman et al., 2006; Trautmann et al.,
2006; Urbani et al., 2006). Notably, PD-L1 mAb had
greater effects than PD-1 mAb during chronic LCMV in-
fection (Barber et al., 2006), and the PD-L1 mAb used
in that study (10F.9G2) blocked both PD-L1:PD-1 and
PD-L1:B7-1 interactions. Further studies are needed to
examine whether a PD-L1 mAb that blocks PD-L1:B7-1
but not PD-L1:PD-1 (e.g., 10F.2H11) can similarly rejuve-
nate exhausted T cells and to investigate the effect of
B7-1 antibodies.
Although the role of B7-1 in controlling T cell activation
is well established, recent work has shown that B7-1 can
also play an intrinsic role in podocytes and DCs. B7-1 on
podocytes in the kidney has been shown to influence cy-
toskeletal distribution and affect kidney function, regulat-118 Immunity 27, 111–122, July 2007 ª2007 Elsevier Inc.ing the development of proteinuria in a mouse model
(Reiser et al., 2004). B7-1 may also influence immune
responses by signaling into DCs. DCs cultured with
CTLA-4-Ig or crosslinking antibodies to B7-1 or B7-2
develop a tolerogenic phenotype (Baban et al., 2005;
Grohmann et al., 2002; Mellor et al., 2004; Munn et al.,
2004), whereas DCs cultured with CD28-Ig develop a
stimulatory phenotype (Orabona et al., 2004). Similarly,
intrinsic signals that activate DCs via the PD-1 ligands
have been reported (Radhakrishnan et al., 2005). Further
studies are needed to determine the effects of PD-L1
engagement of B7-1 on DCs and vice versa.
PD-L1 and B7-1 are both expressed on T cells, B cells,
DCs, and macrophages, suggesting the potential for bidi-
rectional interactions between B7-1 and PD-L1 on these
cell types. Such heterotypic binding has been seen in an-
other immunoglobulin subfamily, the junctional adhesion
molecules (Bazzoni, 2003), and here we report crosstalk
within the B7 family. In addition, PD-L1 on nonhemato-
poietic cells may interact with B7-1 as well as PD-1 on
T cells to protect tissues from autoimmunity (Keir et al.,
2006). Further work is needed to comprehend how T cells
integrate the competing influences of B7-1 binding to
CD28, CTLA-4, and PD-L1.
Our reductionist approach revealed a net inhibitory sig-
nal delivered byB7-1:PD-L1 interactions in vitro. The exact
balance of interactions among these B7 family members
and their receptors is complex and reflects differences in
temporal and spatial expression of these molecules and
their affinities for one another. Our identification of this
new interaction necessitates a reassessment of the roles
of B7-1 and PD-L1 in regulating the activation and inhibi-
tion of immune responses, as well as their therapeutic
manipulation.
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Proteins
Extracellular domains of murine B7-1, B7-2, PD-L1, PD-L2, CTLA-4,
and PD-1 joined to the Fc portion of either the human IgG1 protein
(R&D Systems, Minneapolis, MN) or mouse IgG2a (Chimerigen, Alston,
MA, or kindly provided by M. Collins, Wyeth Pharmaceuticals) were
used.
Expression Cloning
A cDNA library in the pAXEF mammalian expression vector was pre-
pared from CD4 T cells from Cd28/Ctla4/ 129 SvS4Jae mice that
were activated with CD3 mAb plus APCs (T-depleted Cd28/
Ctla4/ 129 SvS4Jae splenocytes stimulated overnight with 5 mg/mL
of CD40 mAb then treated with mitomycin C [50 mg/mL] for 40 min at
37C). RNA was prepared and pooled after 16, 24, and 40 hr.
COS cells were transfected with cDNA library DNA, and plasmids
encoding B7-1 binding proteins were isolated by three rounds of im-
munoselection on plates coated with murine B7-1-IgG2a/goat anti-
mouse IgG2a antibody as described (Freeman et al., 1989). Individual
plasmid DNAs were prepared and sequenced.
Biacore
Protein-protein interactions were measured with a BIAcore 3000 sur-
face plasmon resonance instrument (BIAcore AB, Uppsala, Sweden).
Proteins were covalently coupled to the sensor chip as follows: 0.1 M
N-hydroxysuccinimide (NHS) and 0.4 M N-(3-Dimethylaminopropyl)-
N0-ethylcarbodiimide (EDC) were mixed 1:1 and injected at 10 mL/min
for 10 min over the flow cells. The protein to be coupled was
diluted in 0.1 M sodium acetate buffer (pH 5.5) to a concentration of
50 mg/mL and subsequently injected at 10 mL/min for 10 min. One
flow cell per chip did not receive any protein at this step and served
as a reference channel. To quench any remaining NHS molecules,
1 M ethanolamine was injected at 10 mL/min for 10 min into all flow
cells. The channels were subsequently washed with PBS until a stable
baseline was observed. Subtracting this baseline from the resonance
units (RU) obtained prior to adding protein gave a measure of protein
immobilized in each flow cell. The four flow cells revealed capture of
2000 RU of B7-1-mIgG2a, B7-2-mIgG2a, and control mIgG2a-Fc.
The reverse experiment, where PD-L1 and PD-L2 were immobilized,
revealed capture of 5000–8000 RU of PD-L1-hIgG1, PD-L2-hIgG1,
and control hIgG1-Fc.
All Biacore experiments were performed at 25C. Analyte samples
were injected in randomized order in triplicate. To prevent extreme
sample consumption, a flow rate of 5 or 10 mL/min was used through-
out the binding and dissociation experiments. To provide a double ref-
erence, we injected buffer blanks intermittently throughout the course
of an experiment—at least 40 such blanks were averaged to provide
a reference. Samples or blanks were injected via the KINJECT com-
mand for 6 min and then dissociation was followed for 6 min. Equilib-
rium binding data were analyzed with Scrubber software (University of
Utah Protein Interactions Group) (Roden and Myszka, 1996), and
graphs were made with Statistica (Statsoft) and Adobe Illustrator.
Protein Crosslinking and Mass Spectrometry
B7-1-mIgG2a was dialyzed against 20 mM HEPES buffer (pH 7.0),
concentrated to 3 mM, then mixed with 60-fold molar excess sulfo-
SBED (sulfosuccinimidyl-2-[6-(biotin-amido)-2-(p-azidobenzamido)-
hexanoamido]-ethyl-1,30-dithiopropionate) (Pierce) and incubated at
room temperature for 1 hr in the dark. Nonreacted sulfo-SBED was
removed by spin filter (Microcon YM-10). PD-L1-hIgG1 was dialyzed
against 20 mM HEPES buffer (pH 7.0) and concentrated such that
when added to the mixture above, it was in molar equivalence to the
B7-1. The complex was irradiated at 0C with 302 nm UV light
from a gel box lamp (15W, Alpha Innotech) at a distance of 5 cm for
40 min and subsequently run on a nonreducing SDS-PAGE gel. The
disulfide bond in the sulfo-SBED linker was not cleaved in these
experiments.We identified a band of interest on the gel with a molecular weight
roughly equal to the MW of B7-1-Ig plus PD-L1-Ig. The band was
excised, rinsedwith 50%acetonitrile twice, and subjected to complete
in-gel proteolysis with chymotrypsin. The resulting peptides were
sampled by microcapillary liquid chromatography tandemmass spec-
trometry (LC/MS/MS) via a Thermo Electron LTQ linear ion trap mass
spectrometer. The chymotryptic fragments were interrogated in
a high-resolution MDS Sciex QSTAR quadrupole-TOF mass spec-
trometer (Applied Biosystems). Multiple charged mass-spectral data
were obtained in the range of 390 to 4200 m/z and deconvoluted
with AnalystQS 1.1 software (Applied Biosystems) to produce a peak
list of uncharged monoisotopic peptide masses (M+0H+). To identify
peptides from both proteins that also shared a crosslinker, we used
MS-Bridge version 4.0.7 (Clauser et al., 1999) and manually annotated
the resulting file.
Molecular Model of PD-L1
We developed a structurally biased sequence alignment of mB7-1,
mB7-2, and mPD-L1, by using published crystal structures as a guide
(Davis et al., 2001; Ikemizu et al., 2000; Schwartz et al., 2001; Stamper
et al., 2001). The AUTOMODEL script of the software packageModeler
(Sali and Blundell, 1993) version 8.2 was used to generate a molecular
model of PD-L1. Figures of the B7-1 and PD-L1 models were gener-
ated with Pymol (Delano Scientific).
Preparation of Antibody-Coupled Beads
Combinations of anti-CD3 (clone 2C11), B7-1-hIgG1, or PD-L1-hIgG1
were covalently attached to Dynabeads M450 glycidyl ether beads
according to the manufacturer’s directions (Invitrogen). We ensured
equal loading of proteins during preparation by keeping constant the
molar ratios of the proteins with hamster IgG or hIgG1-Fc antibodies
as filler, as appropriate (Broeren et al., 2000; Riley et al., 2002). In gen-
eral, for each 107 beads, 1 mg of anti-CD3 (20% of total protein) and
4 mg of fusion protein (80%) or control Ig were used.
Adhesion Assay
Mouse pre-B cell line 300.19 was transfected with mB7-1 or mPD-L1
cDNA in the pAXEF expression vector and a plasmid encoding puro-
mycin resistance. Cells were selected in media containing 5 mg/mL
puromycin, sorted, and subcloned. Cell-surface expression of B7-1
or PD-L1 (as appropriate) was verified by FACS (not shown). The cells
were loaded with BCECF (20, 70-(bis-2-carboxyethy1)-5-(and-6)-
carboxyfluorescein) fluorescent dye (Invitrogen) by incubating cells in
a 10 mM solution as per the manufacturer’s directions. A 96-well Max-
isorp plate (Nunc) was coated with PD-L1-hIgG1Fc, PD-L2-hIgG1Fc,
CTLA-4-hIgG1Fc, or control hIgG1Fc overnight at 4C, then washed
with PBS and blocked with 2%BSA in PBS for 2 hr at 37C. Antibodies
that bound PD-L1 were introduced into wells (0.2 mL) as indicated at
40 mg/mL to test the effect on cell adhesion. Cells were suspended
in 0.1% BSA in PBS and loaded into the wells (5 3 104/well), centri-
fuged briefly at 700 rpm (80 3 g), and incubated for 30 min at 37C.
The fluorescence of each well, indicating the number of cells, was
read in a plate reader (Victor-3, PerkinElmer) exciting at 488 nm and
reading at 520 nm. The plate was then washed by gentle inversion in
a 2 L bath of 0.1% BSA in PBS for 30 min at room temperature, allow-
ing nonadherent cells to fall at 1 g, after which the platewas read again.
Experiments were conducted in triplicate wells. Percentage bound
was calculated by dividing the fluorescence before and after the
‘‘wash.’’ Results are reported ±SD by Statistica (StatSoft), and statis-
tical significance was determined by two-tailed, paired Student’s t
test across samples (n = 9 for each group).
Mice
C57BL/6micewere purchased fromThe Jackson Laboratory.Cd28/
Ctla4/ (Mandelbrot et al., 2001) and Pdcd1/ (M.E.K., unpublished
result) mice were generated in our lab. We interbred Cd274/ mice
with Cd28/Ctla4/ mice and confirmed genotypes by PCR
(Keir et al., 2006; Mandelbrot et al., 2001). Likewise, we interbredImmunity 27, 111–122, July 2007 ª2007 Elsevier Inc. 119
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test for PD-1, we used the following deletion-specific primers: 50-ACA
ACA CAG GGT AGG CAT GTA GCA-30, 50-TCC TGC CAA ACC TTG
TAG TCA-30, and 50-GCT AGC CAA CCA GAA GTC TAA-30. PCRs
were run at 94C for 2 min, then 35 cycles of 94C for 1 min, 60C for
1 min, and 72C for 90 s, then 72C for 5 min yielding a KO band of
325 bp and a WT band of 234 bp. Mice were maintained and used
according to institutional and National Institutes of Health guidelines
in a pathogen-free facility. Harvard Medical School is accredited by
the American Association of Accreditation of Laboratory Animal Care.
Mice were sacrificed between 6 and 10 weeks of age.
In Vitro T Cell Experiments
All cell culture was performed with RPMI 1640 (Invitrogen) supple-
mented with 10% FBS (Sigma), 2 mM L-glutamine (Invitrogen),
10 mM HEPES (Invitrogen), penicillin-streptomycin-amphotericin B
(Invitrogen), and 50 mM b-mercaptoethanol (Sigma). CD4 T cells
were purified from spleens via magnetic bead isolation (Miltenyi Bio-
tec) with purity greater than 95% measured by flow cytometry and
plated (105/well in 0.2 mL) in U-bottom tissue-culture wells along
with beads at a 10:1 (bead:T cell) ratio. Cultures were incubated at
37C for 2 days, and then 100 mL supernatant was removed for cyto-
kine analysis and 1 mCi 3H-thymidine was added for 16 hr. Cells
were harvested and radioactivity was counted as described previously
(Latchman et al., 2004). For CFSE dilution experiments, 5 3 105 cells
were labeled with 1 mM CFSE for 13 min, washed, and plated either
as above with beads (106 beads and 105 T cells/well in 96-well U-
bottom tissue-culture plates) or with plate-bound Ig fusion proteins
as in the figure legends (105 T cells/well in 96-well flat-bottom tissue-
culture plates). CFSE-labeled cells were harvested, stained with anti-
CD4 and 7-amino Actinomycin D (7AAD), and analyzed by 4-color
flow cytometry. Data shown were gated on CD4-positive, 7AAD-neg-
ative cells. Statistical comparisons of proliferative responses were
done by two-tailed paired t tests on 3H-thymidine counts (n = 3 for
each group). Statistical comparisons for CFSE data were two-tailed t
tests performed on the percent divided cells as calculated by FlowJo
(TreeStar). Cytokines were measured with the BD Cytokine Bead Array
kit as per the manufacturer’s directions and compared statistically via
a two-tailed t test (n = 3 for each group).
Supplemental Data
Five figures are available at http://www.immunity.com/cgi/content/
full/27/1/111/DC1/.
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